Are there any tests currently ongoing that will give some insight into whether once a week dosing of Rapamycin is superior to once a day for longevity purposes in humans?
Seems to me the once a week theory is based on higher levels of immunity shown in the Mannick study, not necessarily what is best for longevity.
Not that I’m aware of. This was brought up a bit and discussed in the most recent Attia podcast with Sabatini and Kaeberlein. This is an area that needs a lot of work and funding. At a minimum in mice, and ideally in humans, but given that rapamycin is a generic drug nobody is funding human studies with rapamycin these days.
My concern is there may be a rebound effect in MTOR on the once weekly dosage which may actually accelerate aging
@McAlister had a great post in this following thread that suggests we probably don’t need to worry about it too much as long as our dosing is less than 20mg, or equivalent (eg. w/GFJ). Rapamycin / MTOR Rebound effect in 3/12 non-GF and non-Keto patients - #62 by McAlister
I read that dogs are being dosed once weekly as part of the Triad trial. And per a small study, the half-life in dogs is only about 39 hours. If we find out it’s still having an antiaging effect with this schedule, that might help answer this question. I just don’t know how long the wait will be.
Matt has said he expects that the TRIAD dog study results will be available in 2026.